Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

Wed, 13th Mar 2024 20:49

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

PensionBee Group PLC - UK online pension provider - Says revenue increased 35% to GBP23.8 million in 2023 from GBP17.7 million a year prior. Pretax loss narrowed to GBP10.7 million from GBP22.4 million. Adjusted loss before interest, tax, depreciation and amortisation shrunk to GBP8.2 million from GBP19.5 million. Basic loss per share dropped 53% to 4.73p from 9.97p. Assets under administration reached GBP4.35 billion at year-end, up 44% from GBP3.03 billion at the end of 2022. Chief Executive Officer Romi Savova says: "Having met our longstanding and ambitious goal of achieving adjusted Ebitda profitability across the fourth quarter of 2023, we are confident in our continued growth, underpinned by profitability...we have announced our proposed expansion into the US, the world's largest defined contribution pension market, where we see an enormous opportunity to assist many consumers in the US who also struggle to prepare adequately for retirement as they navigate a complex and confusing pensions landscape." Looking ahead, PensionBee says it is aiming to onboard 1 million invested customers, creating a revenue ambition of around GBP150 million in the long term.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based drug discovery and development company - Says its pretax loss widened to EUR30.9 million in 2023 from EUR28.7 million a year prior. The company's net assets totalled a negative EUR15.2 million at year-end, increased from a negative EUR11.5 million at the end of 2022. Says trials of its Bexmarilab cancer immunotherapy candidate made significant progress over the year. Chief Executive Officer Markku Jalkanen says: "Throughout the course of the year, we have reported highly encouraging data for bexmarilimab, showing a remarkable overall response rate in both higher-risk frontline MDS patients as well as HMA-failed MDS patients. These are highly significant findings, given the combinations of treatments these patients had previously failed on and the very limited options available for future therapy. They provide us with a path to market and only bolster our confidence in the potential of this novel immunotherapy to treat patients with aggressive hematological malignancies."

----------

Public Policy Holdings Company Inc - Washington DC-based group of advisory firms specialising in government addairs and public relations - Achieves "record financial performance and excellent strategic progress" in 2023. Revenue grew 24% to USD135.0 million from USD108.8 million. Underlying Ebitda rose 12% to USD35.1 million from USD31.2 million, in line with market expectations. Underlying net income increased 14% to USD26.5 million from USD23.3 million. Basic underlying earnings per share rose 9.7% to 23.54 cents from 21.45 cents. PPHC's annual dividend of 14.30 cents per share was 2.1% ahead of 14.00 cents a year before. All business segments achieved year-on-year growth. The company credits its successful year to several acquisitions, including MultiState Associates Inc, which "contribut[ed] healthily to group revenue and Ebitda" over 2023. PPHC continues to target an Ebitda margin of between 25% and 30%, in line with 2023's 26% margin. Chief Executive Officer Stewart Hall says: "The increasing demand for our services has enabled us to generate solid levels of organic growth and healthy expansion in total client numbers. Strategically, we are progressing well with a healthy pipeline of value accretive acquisition opportunities and the strength of our holding company model being validated by the outperformance of our two most recent acquisitions."

----------

Sovereign Metals Ltd - Graphite development company focused on projects in Malawi - In the half-year ended December 31, the company's operating loss was AUD7.0 million, narrowed from AUD8.5 million a year prior. Exploration and evaluation expenditure totalled AUD5.0 million, down from AUD5.8 million, which the company says stems from the pre-feasibility study at its Kasiya project in Malawi. Interest income grew to AUD938,402 from AUD138,366.

----------

Commonwealth Bank of Australia - Sydney-based financial services company and retail bank - Issues subordinated notes worth USD1.25 billion, due March 2034. The notes were issued pursuant to the company's USD50.00 billion senior and subordinated medium term notes program.

----------

OptiBiotix Health Ltd - life sciences company focused on tackling obesity, high cholesterol, diabetes and skincare - Signs partnership agreement with Dr Morepen Ltd, a New Delhi-based diagnostics company, for the sale of SlimBiome weight-loss products in India under the latter's brand. Chief Executive Officer Stephen O'Hara says: "Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the directors anticipate this agreement could contribute in the region of GBP6-7 million revenue per annum in the next four to five years."

----------

MacFarlane Group PLC - Glasgow-based packaging company - Acquires Allpack Packaging Supplies Ltd, a Bury Saint Edmunds-based packing materials business. Says the "earnings-enhancing acquisition further progresses Macfarlane's strategy to build its protective packaging business through a combination of organic and acquisitive growth". In 2023, Allpack delievered GBP3.0 million in sales alongside Ebitda and pretax profits of GBP600,000. All of Allpack's employees will join MacFarlane. MacFarland will provide a maximum consideration of GBP3.3 million, including a GBP750,000 performance-based earn-out, financed from the company's existing bank facility.

----------

Cora Gold Ltd - gold exploration company focused on Mali and Senegal - Following conversion of USD2.3 million of convertible loan notes for 82.0 million ordinary shares of no par value in the company, has issued an outstanding CLN for a total of USD13.0 million matured on March 12. The company's cash balance is now in excess of USD2.9 million. Chief Executive Officer Bert Monro says: "With strong cash reserves, we look forward to providing progress updates on our Sanankoro gold project in Mali, including submission of the application for a mining permit once the current moratorium is lifted, as well as wider exploration activities across our permits."

----------

Electric Guitar PLC - Reading-based marketing services company - Intends to request the Financial Conduct Authority to cancel the company's shares on the FCA official list and cease admission to trading on the main market of the London Stock Exchange. This is ahead of its proposed application for admission of its shares to trading on AIM. The company expects to convene a shareholder meeting to approve its acquisition of 3radical Ltd in the coming weeks.

----------

Capricorn Energy PLC - Edinburgh-based oil and gas exploration company - Securities and Exchange Board of India has ordered Vedanta Ltd to pay the company USD9.5 million within 45 days. The payment related to a non-payment of a dividend to Capricorn UK Holdings by Vedanta, a Mumbai-based mining company.

----------

Oxford BioDynamics PLC - Oxford-based biotechnology company with a portfolio of clinical tests using its EpiSwitch technology - Announces a fundraising by way of a placing to raise GBP9 million and a retail offer for up to GBP1.3 million, both with an issue price of 9p per share. The issue price represents a 21% discount to the company's closing price of 11.40p on Tuesday. The results of the placing are expects to be released on Thursday. Shares in Oxford BioDynamics closed down 11% at 10.20 pence each in London on Wednesday.

----------

Cooks Coffee Co Ltd - New Zealand-based UK-focused cafe chain - Announces its intention to undertake a placement and share purchase plan. The scheme will result in up to 5.7 million new shares in the company at an issue price of NZD0.20 per share, targeting a raise of up to NZD1.7 million, roughly GBP820,000. Cooks says that the purpose of the fundraise is to invest in improvements in the company's digital programs, including its delivery, click and collect, loyalty programs, as well as expanding its businesses in the Middle East and Europe.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
13 Oct 2022 21:17

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more
5 Apr 2022 20:45

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Mar 2022 13:21

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.